All In Biotech

Drug Trial Radar · NCT07531745

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Dec 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Apr 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Conditions

  • Dravet Syndrome

Interventions

  • ION337Drug

    ION337 will be administered by ITB injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Part 1: up to 6 months; Part 2: up to 31 months
  2. Number of Participants With Clinically Significant Change From Baseline in Safety Laboratory ValuesTime frame: Part 1: up to 6 months; Part 2: up to 31 months
  3. Parts 1 and 2: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Part 1: up to 6 months; Part 2: up to 31 months
  4. Parts 1 and 2: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)Time frame: Part 1: up to 6 months; Part 2: up to 31 months
  5. Parts 1 and 2: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination FindingsTime frame: Part 1: up to 6 months; Part 2: up to 31 months
  6. Parts 1 and 2: Number of Participants with Change in Columbia Suicidality Severity Rating Scale (C-SSRS)Time frame: Part 1: up to 6 months; Part 2: up to 31 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Duke University Health Systems

    Durham, North Carolina · Recruiting

  • The Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania · Recruiting

  • Le Bonheur Children's Hospital

    Memphis, Tennessee · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • McGill University Health Center - Research Institute

    Montreal, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.